Standout Papers

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for ... 2010 2026 2015 2020 490
  1. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) (2010)
    Martin Reck, Joachim von Pawel et al. Annals of Oncology

Immediate Impact

2 by Nobel laureates 6 from Science/Nature 101 standout
Sub-graph 1 of 21

Citing Papers

Immunogenic Cell Death Inducing Metal Complexes for Cancer Therapy
2023 Standout
Biodegradable NIR‐II Pseudo Conjugate Polymeric Nanoparticles Amplify Photodynamic Immunotherapy via Alleviation of Tumor Hypoxia and Tumor‐Associated Macrophage Reprogramming
2023 Standout
6 intermediate papers

Works of V. Gorbounova being referenced

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2010 Standout
P-452 Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender
2005

Author Peers

Author Last Decade Papers Cites
V. Gorbounova 355 392 29 122 7 508
Rinat Galiulin 367 385 32 135 7 550
Eric D. Mininberg 340 304 13 194 6 489
Minhao Fan 304 265 39 174 11 526
Elisa Benedettini 171 223 41 181 9 414
Johann Raats 358 273 36 185 15 552
Magda Bahcall 274 318 23 376 13 571
Philip Tracy 349 467 39 208 6 526
Teresa M. Hopper 195 223 18 238 6 467
Lilian Bu 349 440 113 108 11 535
C. Ligorio 391 330 85 136 7 537

All Works

Loading papers...

Rankless by CCL
2026